HX001
/ Wuhan Houxian Biopharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
An open-label, non-randomized, dose-escalation phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of HX001 in patients with advanced solid tumors
(ChiCTR)
- P1 | N=30 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Wuhan Houxian Biopharmaceutical Co. Ltd.
New P1 trial • Solid Tumor • IL12A
1 to 1
Of
1
Go to page
1